Medical Device

HTG Molecular Diagnostics (NASDAQ:HTGM) a provider of instruments, reagents and services for molecular profiling applications, today announced the completion of its previously announced underwritten public offering of 13,915,000 shares of its common stock at a price to the public of $2.90 per share, including 1,815,000 shares sold pursuant to the exercise in full of the …

HTG Molecular Diagnostics (NASDAQ:HTGM) a provider of instruments, reagents and services for molecular profiling applications, today announced the completion of its previously announced underwritten public offering of 13,915,000 shares of its common stock at a price to the public of $2.90 per share, including 1,815,000 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares.
As quoted in the press release:

All of the shares in the offering were sold by HTG. The aggregate gross proceeds from the offering are approximately $40.4 million, before deducting the underwriting discounts and commissions and offering expenses.

Leerink Partners LLC and Cantor Fitzgerald & Co. acted as joint book-running managers for the offering. H.C. Wainwright & Co., LLC and LifeSci Capital LLC acted as co-managers for the offering.

Click here to read the full press release.

MARKETS

Markets
TSX18861.36-217.28
TSXV617.26-9.08
DOW30775.43-253.88
S&P 5003785.38-33.45
NASD11028.74-149.16
ASX6568.10-132.10

COMMODITIES

Commodities
Gold1798.67-8.20
Silver20.01-0.24
Copper3.62-0.09
Palladium1930.43+8.44
Platinum897.24+0.23
Oil104.92-0.84
Heating Oil3.830.00
Natural Gas5.67+0.25

DOWNLOAD FREE REPORTS

×